checkAd

     113  0 Kommentare Karuna Therapeutics to Present at Upcoming Investor Conferences

    Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that senior management will participate in the following upcoming virtual investor conferences:

    William Blair’s Biotech Focus Conference
    Date: Thursday, August 6, 2020
    Time: 10:00 a.m. EDT

    Wedbush PacGrow Healthcare Virtual Conference
    Date: Tuesday, August 11, 2020
    Time: 10:55 a.m. EDT

    Canaccord Genuity 40th Annual Growth Conference
    Date: Wednesday, August 12, 2020
    Time: 4:00 p.m. EDT

    JMP Securities CNS Forum
    Date: Wednesday, August 19, 2020
    Time: 11:30 a.m. EDT

    A live webcast of the Wedbush presentation will be available on the Investor Relations page of Karuna’s website at investors.karunatx.com. A replay of the webcast will also be archived for up to 90 days on Karuna’s website following the conference.

    About Karuna

    Lesen Sie auch

    Karuna is a clinical-stage biopharmaceutical company committed to developing and delivering first-in-class therapies with the potential to transform the lives of people with CNS disorders – which remain among the most disabling and potentially fatal disorders worldwide. Galvanized by the understanding that today’s neuropsychiatric and pain management patients deserve better, Karuna’s mission is to harness the untapped potential of the brain’s complex biology in pursuit of novel therapeutic pathways that will advance the standard of care. For more information, please visit karunatx.com.




    Business Wire (engl.)
    0 Follower
    Autor folgen

    Karuna Therapeutics to Present at Upcoming Investor Conferences Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric …